anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a pharmaceutical composition comprising a crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base which is a suspension of said crystalline form in a pharmaceutically acceptable excipient, wherein said crystalline form is characterized by a powder X-ray diffraction pattern having characteristic peaks in degrees 2Θ at about 13.3, 17.4 and 19.9. The present invention also relates to a method of treating obesity in a patient in need thereof, comprising subcutaneously administering said pharmaceutical composition. The technical result consists in the possibility of using the crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol according to the present invention in suspensions due to its low solubility in aqueous solutions. Preparing the pharmaceutical composition of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol in the form of a suspension allows to reduce its maximum plasma concentration. Furthermore, the pharmaceutical composition of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol in the form of a suspension provides less prolonged plasma concentration profile of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol depending on post-insertion time. All this allows to avoid a potential undesirable systemic exposure of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol to a body of a patient in need of administering such compositions.
For patients at increased risk of life-threating ventricular arrythmias, hospitalists often administer intravenous magnesium sulfate to maintain total serum magnesium concentration (TsMg) above 2 mg/dL. How long each dose keeps TsMg above this threshold is not well known, however. We collected TsMg values from 12,618 veterans who were given 24,363 doses of intravenous magnesium sulfate during 14,901 hospitalizations for acute heart failure. Across dose amounts, the average TsMg dropped below 2.0 mg/dL within 24 h of administration. When we limited our analysis to 2 g doses (the most common dose) and adjusted for baseline TsMg, estimated glomerular filtration rate, oral magnesium supplementation, and loop diuretic dosing, we found that less than half of the adjusted TsMg values remained above 2.0 mg/dL just 12 h after dose administration. Hospitalists should expect, on average, to administer 2 g intravenous magnesium sulfate at least twice daily to maintain total serum magnesium above 2 mg/dL.
Obesity is a prevalent chronic disease. The management of extreme obesity - i.e., body mass index (BMI) ≥ 50 kg/m2 or obesity class IV and V - is still far from ideal. Individuals with extreme obesity have a high risk of surgical complications, mortality, comorbidities, and reduced weight loss following bariatric surgery. Although lifestyle changes and anti-obesity medications are recommended for all patients with extreme obesity as adjuvants to weight loss, these measures are less effective than bariatric surgery. As a first step, sleeve gastrectomy or an inpatient very-low-calorie diet should be incentivized to enhance weight loss before definitive surgery. Although malabsorptive procedures lead to greater weight loss, they are associated with an increased risk of early complications and malnutrition. Nonstandard techniques employed in clinical trial protocols, such as transit bipartition, may be performed as they maintain a weight loss potency comparable to that of the classic duodenal switch but with fewer nutritional problems. Anatomical causes should be investigated in patients with postoperative suboptimal clinical response or recurrent weight gain. In these cases, the initiation of anti-obesity drugs, endoscopic therapies, or a conversion procedure might be recommended. More studies are needed to address the specific population of patients with extreme obesity, as their outcomes are expected to be distinct from those of patients with lower BMI.
Pregnancy Category C

There are no adequate and well-controlled studies of glimepiride in pregnant women. In animal studies there was no increase in congenital anomalies, but an increase in fetal deaths occurred in rats and rabbits at glimepiride doses 50 times (rats) and 0.1 times (rabbits) the maximum recommended human dose (based on body surface area). This fetotoxicity, observed only at doses inducing maternal hypoglycemia, is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride and has been similarly noted 

with other sulfonylureas. Glimepiride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because data suggest that abnormal blood glucose during pregnancy is associated with a higher incidence of congenital abnormalities, diabetes treatment during pregnancy should maintain blood glucose as close to normal as possible. 

Nonteratogenic Effects: Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery.
Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
Acute Coronary Syndrome (ACS) is the leading cause of death worldwide. Differentiating ACS from other non-ischemic chest pain is imperative in emergency medicine and missed myocardial infarction remains one of the highest sources of medical malpractice in Emergency Departments (ED). At the same time, economic pressures and limited resources demand that physicians avoid hospital admission or protracted observation for every patient with chest pain or suspicious symptoms. In the absence of clear ST elevation (STE) on the electrocardiogram (ECG), ED providers have no reliable tools to quickly triage non-STE (NSTE) ACS patients. Current guidelines rely on blood biomarkers (e.g. cardiac enzymes) to identify this syndrome and do not completely describe ischemic ECG changes associated with it. ED Providers will need to delay the management of these high risk patients until cardiac biomarkers are withdrawn, analyzed, and interpreted. This results in greater mortality rates in NSTE-ACS patients and overburdens the healthcare system. The prolonged observation times at EDs and unnecessary admissions are just additional consequences that overuse nursing times and exacerbate nursing shortage.

ECG changes other than ST elevation and dynamic ECG changes are a rich opportunity for improving diagnostics. This proposal intends to provide new insights into how ischemic repolarization changes evolve over time in the subacute phase of myocardial ischemia. Sixty patients with suspected coronary artery disease referred for nuclear cardiac stress testing will be included. Resting 12-lead ECGs will be obtained before the stress test and one after the stress test but before the nuclear scan. Alterations in novel, computerized T wave indices will be correlated with focal myocardial ischemia seen on nuclear scans. Repeated Measures ANOVA with between group comparisons, and Generalized Estimation Equation will be used in the analysis. The results will provide insight on the diagnostic value of different novel T wave indices to detect myocardial ischemia. Results from this study will provide tools for ED providers to distinguish ACS from non-ischemic chest pain patients early in the triage process, especially in the absence of STE that constitutes the common standard nowadays.
Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
The present invention provides a Chinese medicinal preparation for treating the disease symptoms of lithiasis in the urinary system, urethral infection, etc. The Chinese medicinal preparation comprises the main raw materials of snowbelleaf tickclover herb, plantain herb, pyrrosia leaf and corn stigma. The production method of the Chinese medicinal preparation comprises the steps that the snowbelleaf tickclover herb, the plantain herb, the pyrrosia leaf and the corn stigma are respectively cleaned, selected, washed and cut into segments (or broken); 6 to 10 times of water is added into each kilogram of medicinal materials for decoction twice; the medicinal materials are filtered, and the filter liquid is concentrated; then, the concentrated liquid is mixed with excipient to prepare tablets, capsules, pills, granules, mixture and syrup. The Chinese medicinal preparation has the advantages of clearing heat, expelling dampness, promoting diuresis, treating lithiasis, relieving inflammation and alleviating pain. The Chinese medicinal preparation is used for treating damp and heat in the bladder, heat strangury, urolithic strangury, strangury, urethral infection, urinary calculus and renal colic. The Chinese medicinal preparation can be used as an auxiliary medicine for extracorporeal ultrasonic for treating ithiasis. The Chinese medicinal preparation has the obvious effects of alleviating pain, relieving inflammation, promoting diuresis and treating lithiasis, and also has a good therapeutic effect on frequent urination, urgency of urination and painful urination caused by urethral infection.
PURPOSE:To provide the subject antinephritic agent containing one or more of berberine, pachyman or coptisine as the active components. CONSTITUTION:One or more selected from berberine of formula I, i.e., an alkaloid contained, e.g. in galenical drug Coptic rhizome, coptisine of formula II and pachyman (e.g. beta-pachyman of formula III), i.e., a polysaccharide contained in galenical drug hoelen, etc., and having a structure composed of many glucoses bonded through 1 3 bond are used as the active components. The above- mentioned agent can be administrated in any dosage form as an oral preparation and a parenteral preparation. In order to exhibit the prescribed effect, a daily oral dose of 30mg to 3g is used suitably divided in several times or 0.1-500mg/ day is parenterally administrated in a dosage form of intravenous injection, intravenous drip infusion, subcutaneous injection or intramuscular injection.
The current invention relates to two isoforms, p110 and p58 of PITSLRE protein kinase, which can be translated from the same p110 (.alpha.2-2) mRNA by an internal ribosome entry process. This means that p110 and p58, two proteins with putative different functions, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 439 C-terminal amino acids that contain the kinase domain. The IRES in the polycistronic p110 mRNA is the first IRES completely localized in the coding region of a cellular mRNA. Moreover, it was unexpectedly found that the IRES  element is cell cycle regulated. Translation of p58 occurs in the G2/M stage of the cell cycle.
BACKGROUND: Pontocerebellar hypoplasia type 10 (PCH10) due to CLP1 gene mutations is characterized by structural brain anomalies, progressive microcephaly, severe intellectual and physical disabilities, and spasticity. In this follow-up study, evolution of phenotypic and neurological characteristics of patients with PCH10 is discussed.
METHODS: Phenotype, growth parameters, motor functions, developmental tests, spasticity assessments, functional independence assessments, electroencephalography (EEG), and brain magnetic resonance imaging (MRI) of 10 patients with PCH10 were monitored on separate examinations. Alterations were recorded.
RESULTS: Patients were followed-up for an average of 2.83 years. The tone of the upper extremities was significantly higher than that of the lower extremities, according to Modified Ashworth Scale (MAS) values. Sixty percent of patients could sit unsupported; 20% achieved supported sitting initially but lost the ability during follow-up. Absence of grabbing or sitting was observed in 20% of patients. During follow-up, one person achieved supported sitting and one person achieved head holding. Only one patient was able to speak a few words. Cerebellar atrophy (two of 10), pons hypoplasia (four of 10), cortical atrophy (seven of 10), enlarged ventricles (10 of 10), thinning of the corpus callosum (10 of 10), hypomyelination (six of 10), and increased white matter signal intensity (six of 10) were the observed MRI findings.
CONCLUSIONS: Progressive cerebral and cerebellar atrophy was demonstrated radiologically for the first time in a PCH10 cohort. It is of crucial importance to identify these patients promptly with the help of dysmorphic findings and spasticity being pronounced in the upper extremities. Furthermore, we note that phenotypic and neurological examination findings tend to change slightly over time.
Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
PROSCAR is contraindicated in pregnant females and in females who may potentially be pregnant and not indicated for use in females. Based on animal studies and the mechanism of action, PROSCAR may cause abnormal development of external genitalia in a male fetus if administered to a pregnant female. Females who are pregnant or may potentially be pregnant should not handle crushed or broken PROSCAR tablets. PROSCAR tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed. If a pregnant female comes in contact with crushed or broken PROSCAR tablets, the contact area should be washed immediately with soap and water. [See Contraindications (4), Use in Specific Populations (8.1), Clinical Pharmacology (12.1 and 12.3), and How Supplied/Storage and Handling (16).]
Derivatives of cephalosporin of general formula <FORM:1101424/C2/1> in which R1 is acyl and wherein the pyridine may be nuclear substituted, are obtained by reacting a sulphur compound of general formula <FORM:1101424/C2/2> in which R2 is acyl or hydrogen; -S-Y is the residue of a nucleophile and X is a cation; with pyridine or a nuclear substituted pyridine in a reaction medium containing dissolved therein a salt of mercury, silver or gold, said salt being able to complex with the pyridine reagent and to ionize in water, the resulting compound where R2 represents hydrogen thereafter being acylated.  The salt should preferably be an anion of a strong acid and should be non-oxidizing to compound V, e.g. the nitrate, perchlorate, trifluoroacetate and tetrafluoroborate. Instead of the metal salt and compound V, a salt of compound V with the metal or compound V with a complex of the metal salt with the pyridine reagent may be used. The reaction medium may be (a) aqueous or (b) non-aqueous.  For (a) water or a mixture of water and a water-miscible organic solvent is used at 20 DEG  to 100 DEG  C. Excess metal ions are removed by precipitation and purification is by percolation through an anion exchange resin. For (b) the reaction medium may be an alkanoic acid nitrile, a halogenated hydrocarbon, a nitroalkane, a nitro-aromatic compound, a cyclic ether, amides, e.g. formamide and N-methylformamide, N-methyl-pyrrolidone and a dialkylsulphoxide.  The reactants are heated at 50 DEG  C. and a solid, e.g. acetamide liquid at 50 DEG  C. may be used as reaction medium. Compounds of Formula V may be prepared by the methods of Specifications 1,012,943 and 1,059,562.  A wide range of acyl (R1) groups are mentioned including those of Specifications 1,054,806, 1,082,962 and in Specification 1,082,943.  Typical mercuric and silver salts include the perchlorate, nitrate, trifluoroacetate and tetrafluoroborate.  A complex of the pyridine reagent and the metal salt may also be used instead of the simple metal salts.
Acid-sensing ion channels (ASICs), which act as proton-gating sodium channels, have garnered attention as pharmacological targets. ASIC1a isoform, notably prevalent in the central nervous system, plays an important role in synaptic plasticity, anxiety, neurodegeneration, etc. In the peripheral nervous system, ASIC1a shares prominence with ASIC3, the latter well established for its involvement in pain signaling, mechanical sensitivity, and inflammatory hyperalgesia. However, the precise contributions of ASIC1a in peripheral functions necessitate thorough investigation. To dissect the specific roles of ASICs, peptide ligands capable of modulating these channels serve as indispensable tools. Employing molecular modeling, we designed the peptide targeting ASIC1a channel from the sea anemone peptide Ugr9-1, originally targeting ASIC3. This peptide (A23K) retained an inhibitory effect on ASIC3 (IC50 9.39 µM) and exhibited an additional inhibitory effect on ASIC1a (IC50 6.72 µM) in electrophysiological experiments. A crucial interaction between the Lys23 residue of the A23K peptide and the Asp355 residue in the thumb domain of the ASIC1a channel predicted by molecular modeling was confirmed by site-directed mutagenesis of the channel. However, A23K peptide revealed a significant decrease in or loss of analgesic properties when compared to the wild-type Ugr9-1. In summary, using A23K, we show that negative modulation of the ASIC1a channel in the peripheral nervous system can compromise the efficacy of an analgesic drug. These results provide a compelling illustration of the complex balance required when developing peripheral pain treatments targeting ASICs.
3594. Newton, P. A., [Farbenfabriken vorm. F. Bayer & Co.]. Feb. 13. Medicines for internal use; hypodermic injections.-A therapeutical compound for internal or subcutaneous administration consists of a mixture of a cholesterin ester, such as the oleate, with an ester of a high molecular fatty acid such as ethyl oleate, methyl palmitate, olive oil, or phenyl palmitate.. The mixtures are stated to have lower melting - points than the pure cholesterin esters.
Screening tests, cognitive function tests, brain MRI, and amyloid PET are performed on subjects who voluntarily consent in writing to participate in the trial to determine whether they meet the inclusion/exclusion criteria. Randomization is assigned to eligible subjects. The experimental groups are irradiated six times for 3 weeks according to the radiation dose determined for each group, and the control group is irradiated with sham radiation. The patients assigned to the experimental group receive whole brain irradiation with 6 MV energy using a linear accelerator. In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
Purpose: In this study, the contribution of this non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography

Method: This study is a prospective clinical study. Between October 2020- November 2022, EtCO2 and IPI follow-up of 0-18 year-old pediatric patients diagnosed with DKA in the Pediatric Emergency Service of Akdeniz University Medical Faculty Hospital was performed by capnography. DKA diagnosis, grading, clinical follow-up and treatment termination criteria of the patients were determined according to the ISPAD 2018 Diagnosis and Treatment Guidelines. In the study; During the clinical follow-up, changes in GCS, blood glucose, vital, blood gas and capnograph parameters were examined. Demographic data were analyzed in all patients and in groups of patients who underwent DKA grading. GCS, blood gas and capnograph parameters were compared in the patient groups with DKA grading. Diagnostic test performances of blood gas and capnograph parameters were compared to detect low GCS
BACKGROUND: Intravenous (IV) therapy using short peripheral IV catheters (PIVC) is commonplace with neonatal patients. However, this therapy is associated with high complication rates including the leakage of infused fluids from the vasculature into the surrounding tissues; a condition referred to as, peripheral IV infiltration/extravasation (PIVIE).
OBJECTIVE: The quality improvement project aimed to identify the prevalence of known risk factors for PIVIE in the neonatal intensive care unit (NICU) and explore the feasibility of using novel optical sensor technology to aid in earlier detection of PIVIE events.
METHODS: The plan, do, study, act (PDSA) model of quality improvement (QI) was used to provide a systematic framework to identify PIVIE risks and evaluate the potential utility of continuous PIVC monitoring using the ivWatch model 400® system. The site was provided with eight monitoring systems and consumables. Hospital staff were supported with theoretical education and bedside training about the system operations and best use practices.
RESULTS: In total 113 PIVIE's (graded II-IV) were recorded from 3476 PIVCs, representing an incidence of 3.25%. Lower birth weight and gestational age were statistically significant factors for increased risk of PIVIE (p = 0.004); all other known risk factors did not reach statistical significance. Piloting the ivWatch with 21 PIVCs using high-risk vesicant solutions over a total of 523.9 h (21.83 days) detected 11 PIVIEs (graded I-II). System sensitivity reached 100%; 11 out of 11 PIVIEs were detected by the ivWatch before clinician confirmation.
CONCLUSIONS: Prevailing risk factors for PIVIE in the unit were comparable to those published. Continuous infusion site monitoring using the ivWatch suggests this technology offers the potential to detect PIVIE events earlier than relying on intermittent observation alone (i.e. the current standard of care). However, large-scale study with neonatal populations is required to ensure the technology is optimally configured to meet their needs.
Chimeric kanamycin resistance genes are disclosed. The chimeric genes comprise a nucleotide sequence that encodes ANT(4')-IA enzyme operably linked to a heterologous promoter and a heterologous termination sequence. Plasmids that comprise the chimeric kanamycin resistance gene are disclosed. Bacterial cells that comprise the chimeric gene on a plasmid or integrated into the bacterial genome are disclosed. Methods of producing plasmids are disclosed. Pharmaceutical compositions comprising plasmids that include the chimeric genes are disclosed. Methods of enhancing growth of bacterial cells are disclosed. Plasmids which comprise the chimeric kanamycin resistance gene and the sequences from herpes simplex virus gene HSVgD2 or human immunodeficiency virus are disclosed.